This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Proteon Therapeutics Announces Positive Phase 2 Trial Results Of PRT-201 In Chronic Kidney Disease Patients Undergoing Surgical Placement Of An Arteriovenous Fistula For Hemodialysis

"Our lead product, PRT-201, represents a highly innovative approach to addressing the significant challenges associated with vascular access in patients with CKD, and we are very excited about the potential for PRT-201 to dramatically improve care for dialysis patients," said Timothy P. Noyes, President and CEO of Proteon. "Based on the positive results from this Phase 2 study, Proteon intends to advance PRT-201 into Phase 3 studies."

Proteon is conducting a robust clinical research program evaluating PRT-201's ability to improve vascular outcomes. Proteon previously completed a Phase 1/2 AVF study, the results of which were recently published in the Journal of Vascular Access, and recently completed follow-up in a Phase 1/2 study in patients undergoing surgical placement of an arteriovenous graft (AVG). The AVG study results are expected in the first half of 2013. In October 2012, Proteon initiated enrollment in a Phase 1 study in which PRT-201 is delivered via a catheter following angioplasty of the superficial femoral or popliteal artery in patients with symptomatic peripheral artery disease.

About PRT-201PRT-201 is an investigational recombinant human elastase that is being studied for its ability to improve outcomes in patients suffering from vascular disease. Elastase has been shown in certain preclinical settings to reduce neointimal hyperplasia formation and to cause dilation of segments of arteries and veins. These effects may decrease stenosis and prolong vessel patency. Improved patency may lead to fewer corrective surgical procedures, fewer hospitalizations, lower costs and less suffering for patients. PRT-201 has received fast track and orphan drug designations from the FDA for the indication of improving AVF and AVG surgical outcomes.

About Proteon Therapeutics Proteon Therapeutics, Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, MA., and has research facilities in Kansas City, MO. For additional information, please visit .

SOURCE Proteon Therapeutics, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs